OOMA INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OOMA INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jan 31, 2018 | $114.49M | Apr 2, 2018 |
| FY2018 | Jan 31, 2017 | $104.52M | Apr 2, 2018 |
| FY2018 | Jan 31, 2016 | $88.78M | Apr 2, 2018 |
| FY2017 | Jan 31, 2015 | $72.20M | Apr 11, 2017 |
| FY2016 | Jan 31, 2014 | $53.67M | Apr 13, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $167.24M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | $156.02M | Apr 3, 2026 |
| FY2026 | Jan 31, 2024 | $147.23M | Apr 3, 2026 |
| FY2025 | Jan 31, 2023 | $137.65M | Apr 1, 2025 |
| FY2024 | Jan 31, 2022 | $118.44M | Apr 2, 2024 |
| FY2023 | Jan 31, 2021 | $104.80M | Apr 7, 2023 |
| FY2022 | Jan 31, 2020 | $89.38M | Apr 8, 2022 |
| FY2021 | Jan 31, 2019 | $76.49M | Apr 7, 2021 |
| FY2020 | Jan 31, 2018 | $68.09M | Apr 14, 2020 |
| FY2019 | Jan 31, 2017 | $59.33M | Apr 3, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $6.46M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | ($6.90M) | Apr 3, 2026 |
| FY2026 | Jan 31, 2024 | ($835.0K) | Apr 3, 2026 |
| FY2025 | Jan 31, 2023 | ($3.66M) | Apr 1, 2025 |
| FY2024 | Jan 31, 2022 | ($1.75M) | Apr 2, 2024 |
| FY2023 | Jan 31, 2021 | ($2.44M) | Apr 7, 2023 |
| FY2022 | Jan 31, 2020 | ($18.80M) | Apr 8, 2022 |
| FY2021 | Jan 31, 2019 | ($14.57M) | Apr 7, 2021 |
| FY2020 | Jan 31, 2018 | ($13.12M) | Apr 14, 2020 |
| FY2019 | Jan 31, 2017 | ($12.95M) | Apr 3, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $4.26M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | ($6.94M) | Apr 3, 2026 |
| FY2026 | Jan 31, 2024 | ($4.00M) | Apr 3, 2026 |
| FY2025 | Jan 31, 2023 | ($5.76M) | Apr 1, 2025 |
| FY2024 | Jan 31, 2022 | ($1.93M) | Apr 2, 2024 |
| FY2023 | Jan 31, 2021 | ($2.78M) | Apr 7, 2023 |
| FY2022 | Jan 31, 2020 | ($19.71M) | Apr 8, 2022 |
| FY2021 | Jan 31, 2019 | ($15.79M) | Apr 7, 2021 |
| FY2020 | Jan 31, 2018 | ($13.72M) | Apr 14, 2020 |
| FY2019 | Jan 31, 2017 | ($13.28M) | Apr 3, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $50.26M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | $54.29M | Apr 3, 2026 |
| FY2026 | Jan 31, 2024 | $49.94M | Apr 3, 2026 |
| FY2025 | Jan 31, 2023 | $45.94M | Apr 1, 2025 |
| FY2024 | Jan 31, 2022 | $38.19M | Apr 2, 2024 |
| FY2023 | Jan 31, 2021 | $36.08M | Apr 7, 2023 |
| FY2022 | Jan 31, 2020 | $37.77M | Apr 8, 2022 |
| FY2021 | Jan 31, 2019 | $33.90M | Apr 7, 2021 |
| FY2020 | Jan 31, 2018 | $29.33M | Apr 14, 2020 |
| FY2019 | Jan 31, 2017 | $24.24M | Apr 3, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $27.69M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | $26.61M | Apr 3, 2026 |
| FY2026 | Jan 31, 2024 | $12.27M | Apr 3, 2026 |
| FY2025 | Jan 31, 2023 | $8.77M | Apr 1, 2025 |
| FY2024 | Jan 31, 2022 | $6.66M | Apr 2, 2024 |
| FY2023 | Jan 31, 2021 | $4.37M | Apr 7, 2023 |
| FY2022 | Jan 31, 2020 | ($7.56M) | Apr 8, 2022 |
| FY2021 | Jan 31, 2019 | ($3.93M) | Apr 7, 2021 |
| FY2020 | Jan 31, 2018 | $3.17M | Apr 14, 2020 |
| FY2019 | Jan 31, 2017 | $385.0K | Apr 3, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $5.59M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | $6.45M | Apr 3, 2026 |
| FY2026 | Jan 31, 2024 | $6.16M | Apr 3, 2026 |
| FY2025 | Jan 31, 2023 | $5.21M | Apr 1, 2025 |
| FY2024 | Jan 31, 2022 | $4.20M | Apr 2, 2024 |
| FY2023 | Jan 31, 2021 | $3.16M | Apr 7, 2023 |
| FY2022 | Jan 31, 2020 | $3.27M | Apr 8, 2022 |
| FY2021 | Jan 31, 2019 | $1.92M | Apr 7, 2021 |
| FY2018 | Jan 31, 2018 | $2.48M | Apr 2, 2018 |
| FY2018 | Jan 31, 2017 | $1.56M | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $227.54M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | $149.20M | Apr 3, 2026 |
| FY2025 | Jan 31, 2024 | $159.25M | Apr 1, 2025 |
| FY2024 | Jan 31, 2023 | $131.01M | Apr 2, 2024 |
| FY2023 | Jan 31, 2022 | $109.25M | Apr 7, 2023 |
| FY2022 | Jan 31, 2021 | $89.10M | Apr 8, 2022 |
| FY2021 | Jan 31, 2020 | $80.61M | Apr 7, 2021 |
| FY2020 | Jan 31, 2019 | $78.39M | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | $73.43M | Apr 3, 2019 |
| FY2018 | Jan 31, 2017 | $73.34M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $134.62M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | $63.92M | Apr 3, 2026 |
| FY2025 | Jan 31, 2024 | $81.17M | Apr 1, 2025 |
| FY2024 | Jan 31, 2023 | $67.86M | Apr 2, 2024 |
| FY2023 | Jan 31, 2022 | $58.20M | Apr 7, 2023 |
| FY2022 | Jan 31, 2021 | $49.55M | Apr 8, 2022 |
| FY2021 | Jan 31, 2020 | $52.20M | Apr 7, 2021 |
| FY2020 | Jan 31, 2019 | $45.34M | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | $36.36M | Apr 3, 2019 |
| FY2018 | Jan 31, 2017 | $33.52M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $92.92M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | $85.28M | Apr 3, 2026 |
| FY2026 | Jan 31, 2024 | $78.09M | Apr 3, 2026 |
| FY2026 | Jan 31, 2023 | $63.14M | Apr 3, 2026 |
| FY2025 | Jan 31, 2022 | $51.06M | Apr 1, 2025 |
| FY2024 | Jan 31, 2021 | $39.55M | Apr 2, 2024 |
| FY2023 | Jan 31, 2020 | $28.42M | Apr 7, 2023 |
| FY2022 | Jan 31, 2019 | $33.05M | Apr 8, 2022 |
| FY2021 | Jan 31, 2018 | $37.07M | Apr 7, 2021 |
| FY2020 | Jan 31, 2017 | $39.82M | Apr 14, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $49.83M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | $23.07M | Apr 3, 2026 |
| FY2025 | Jan 31, 2024 | $23.07M | Apr 1, 2025 |
| FY2024 | Jan 31, 2023 | $8.66M | Apr 2, 2024 |
| FY2023 | Jan 31, 2022 | $4.26M | Apr 7, 2023 |
| FY2022 | Jan 31, 2021 | $4.26M | Apr 8, 2022 |
| FY2021 | Jan 31, 2020 | $4.26M | Apr 7, 2021 |
| FY2020 | Jan 31, 2019 | $3.90M | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | $1.95M | Apr 3, 2019 |
| FY2018 | Jan 31, 2017 | $1.12M | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | ($133.72M) | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | ($140.18M) | Apr 3, 2026 |
| FY2025 | Jan 31, 2024 | ($133.28M) | Apr 1, 2025 |
| FY2024 | Jan 31, 2023 | ($132.44M) | Apr 2, 2024 |
| FY2023 | Jan 31, 2022 | ($128.79M) | Apr 7, 2023 |
| FY2022 | Jan 31, 2021 | ($127.04M) | Apr 8, 2022 |
| FY2021 | Jan 31, 2020 | ($124.60M) | Apr 7, 2021 |
| FY2020 | Jan 31, 2019 | ($105.80M) | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | ($90.93M) | Apr 3, 2019 |
| FY2018 | Jan 31, 2017 | ($77.81M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $20.14M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | $17.87M | Apr 3, 2026 |
| FY2025 | Jan 31, 2024 | $17.54M | Apr 1, 2025 |
| FY2024 | Jan 31, 2023 | $24.14M | Apr 2, 2024 |
| FY2023 | Jan 31, 2022 | $19.67M | Apr 7, 2023 |
| FY2022 | Jan 31, 2021 | $17.30M | Apr 8, 2022 |
| FY2022 | Jan 31, 2020 | $11.68M | Apr 8, 2022 |
| FY2022 | Jan 31, 2019 | $15.37M | Apr 8, 2022 |
| FY2021 | Jan 31, 2018 | $4.48M | Apr 7, 2021 |
| FY2020 | Jan 31, 2017 | $3.99M | Apr 14, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $51.51M | Apr 3, 2026 |
| FY2025 | Jan 31, 2025 | $0 | Apr 1, 2025 |
| FY2025 | Jan 31, 2024 | $16.00M | Apr 1, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 0 | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | 0 | Apr 3, 2026 |
| FY2026 | Jan 31, 2024 | 0 | Apr 3, 2026 |
| FY2025 | Jan 31, 2023 | 0 | Apr 1, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Apr 2, 2024 |
| FY2023 | Jan 31, 2021 | 0 | Apr 7, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 0 | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | 0 | Apr 3, 2026 |
| FY2026 | Jan 31, 2024 | 0 | Apr 3, 2026 |
| FY2025 | Jan 31, 2023 | 0 | Apr 1, 2025 |
| FY2024 | Jan 31, 2022 | 0 | Apr 2, 2024 |
| FY2023 | Jan 31, 2021 | 0 | Apr 7, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | 27.40M | Apr 3, 2026 |
| FY2026 | Jan 31, 2025 | 27.20M | Apr 3, 2026 |
| FY2025 | Jan 31, 2024 | 26.00M | Apr 1, 2025 |
| FY2024 | Jan 31, 2023 | 25.00M | Apr 2, 2024 |
| FY2023 | Jan 31, 2022 | 23.90M | Apr 7, 2023 |
| FY2022 | Jan 31, 2021 | 22.90M | Apr 8, 2022 |
| FY2021 | Jan 31, 2020 | 21.70M | Apr 7, 2021 |
| FY2020 | Jan 31, 2019 | 20.30M | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | 19.10M | Apr 3, 2019 |
| FY2018 | Jan 31, 2017 | 18.00M | Apr 2, 2018 |